Loading…

Loading grant details…

Completed HORIZON European Commission

Homeoproteins as novel therapies for neurodegenerative diseases

€5.52M EUR

Funder European Commission
Recipient Organization Brainever
Country France
Start Date Nov 01, 2022
End Date Oct 31, 2024
Duration 730 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190105256
Grant Description

With the ageing of the population, neurodegenerative diseases will be a huge societal, health and economic problem. There are no effective solutions that can stop the progression of these devastating diseases.

At BrainEver we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs).

Homeoproteins are endogenous proteins expressed in diverse neuronal types, where they regulate age-dependent mechanisms related to neurodegeneration.

When homeoproteins are injected into the central nervous system of animals with disease, neuronal survival and function is restored, halting degeneration. This suggests a huge potential as therapies for neurodegenerative diseases.

In this project, we aim to develop and clinically validate a revolutionary therapy using the homeoprotein Engrailed-1, to treat patients with Amyotrophic Lateral Sclerosis (ALS) and Parkinsons Disease (PD).

All Grantees

Brainever

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant